Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211071 | 1.00 | PTGER4 (0.45) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3139056 | 0.85 | PTGER4 (0.55) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2427070 | 0.85 | PTGER4 (0.57) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2427076 | 0.85 | PTGER4 (0.57) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2211076 | 0.84 | PTGER4 (0.49) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2211135 | 0.84 | PTGER4 (0.49) | PTGER4PTGER3PTGER2 | |
| SCHEMBL12324925 | 0.84 | PTGER4 (0.48) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3675239 | 0.80 | PTGER4 (0.61) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3683263 | 0.79 | PTGER4 (0.52) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3682249 | 0.77 | PTGER4 (0.62) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| US-7053085-B2 | A piperidin-2-one, 1,3-oxazinan-2-one, or 1,3-thiazinan-2-one compound for treatment of glaucoma, mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts; 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; side effect reduction | MERCK & CO. INC. (US) | 2006-05-30 | — | — | US | disclosed |